Sanginita Chemicals Limited

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, UPL.BO has a market cap of 528.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while UPL.BO trades at ₹635.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas UPL.BO's P/E ratio is 29.90. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to UPL.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is more volatile compared to UPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check UPL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, FLUOROCHEM.NS has a market cap of 383.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while FLUOROCHEM.NS trades at ₹3,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas FLUOROCHEM.NS's P/E ratio is 58.44. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to FLUOROCHEM.NS's ROE of +0.09%. Regarding short-term risk, SANGINITA.NS is more volatile compared to FLUOROCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check FLUOROCHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DEEPAKNI.BO has a market cap of 332.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DEEPAKNI.BO trades at ₹2,436.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DEEPAKNI.BO's P/E ratio is 57.46. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKNI.BO's ROE of +0.06%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DEEPAKNI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKNI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, NAVINFLUOR.NS has a market cap of 329.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while NAVINFLUOR.NS trades at ₹6,492.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas NAVINFLUOR.NS's P/E ratio is 59.70. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NAVINFLUOR.NS's ROE of +0.19%. Regarding short-term risk, SANGINITA.NS is more volatile compared to NAVINFLUOR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check NAVINFLUOR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, NAVINFLUOR.BO has a market cap of 329.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while NAVINFLUOR.BO trades at ₹6,467.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas NAVINFLUOR.BO's P/E ratio is 59.64. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NAVINFLUOR.BO's ROE of +0.19%. Regarding short-term risk, SANGINITA.NS is more volatile compared to NAVINFLUOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check NAVINFLUOR.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DEEPAKNTR.BO has a market cap of 215.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DEEPAKNTR.BO trades at ₹1,605.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DEEPAKNTR.BO's P/E ratio is 40.47. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKNTR.BO's ROE of +0.06%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DEEPAKNTR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKNTR.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DEEPAKNTR.NS has a market cap of 215.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DEEPAKNTR.NS trades at ₹1,593.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DEEPAKNTR.NS's P/E ratio is 40.41. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKNTR.NS's ROE of +0.10%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DEEPAKNTR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKNTR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, BAYERCROP.BO has a market cap of 212.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while BAYERCROP.BO trades at ₹4,685.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas BAYERCROP.BO's P/E ratio is 31.67. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to BAYERCROP.BO's ROE of +0.23%. Regarding short-term risk, SANGINITA.NS is more volatile compared to BAYERCROP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check BAYERCROP.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, TATACHEM.NS has a market cap of 183.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while TATACHEM.NS trades at ₹716.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas TATACHEM.NS's P/E ratio is 112.57. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to TATACHEM.NS's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is more volatile compared to TATACHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check TATACHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, TATACHEM.BO has a market cap of 183.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while TATACHEM.BO trades at ₹714.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas TATACHEM.BO's P/E ratio is 112.50. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to TATACHEM.BO's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is more volatile compared to TATACHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check TATACHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DEEPAKFERT.NS has a market cap of 124.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DEEPAKFERT.NS trades at ₹984.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DEEPAKFERT.NS's P/E ratio is 14.27. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKFERT.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DEEPAKFERT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKFERT.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DEEPAKFERT.BO has a market cap of 124.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DEEPAKFERT.BO trades at ₹984.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DEEPAKFERT.BO's P/E ratio is 14.26. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKFERT.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DEEPAKFERT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKFERT.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, SPLPETRO.NS has a market cap of 121.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while SPLPETRO.NS trades at ₹651.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas SPLPETRO.NS's P/E ratio is 45.44. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SPLPETRO.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to SPLPETRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check SPLPETRO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ACI.NS has a market cap of 72.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ACI.NS trades at ₹584.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ACI.NS's P/E ratio is 49.72. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ACI.NS's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ACI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ACI.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ACI.BO has a market cap of 72.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ACI.BO trades at ₹581.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ACI.BO's P/E ratio is 49.75. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ACI.BO's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ACI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ACI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GNFC.BO has a market cap of 67.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GNFC.BO trades at ₹457.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GNFC.BO's P/E ratio is 10.59. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GNFC.BO's ROE of +0.07%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GNFC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GNFC.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GNFC.NS has a market cap of 67.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GNFC.NS trades at ₹456.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GNFC.NS's P/E ratio is 10.78. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GNFC.NS's ROE of +0.07%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GNFC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GNFC.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INDIAGLYCO.NS has a market cap of 62.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INDIAGLYCO.NS trades at ₹918.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INDIAGLYCO.NS's P/E ratio is 21.50. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDIAGLYCO.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INDIAGLYCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDIAGLYCO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INDIAGLYCO.BO has a market cap of 62.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INDIAGLYCO.BO trades at ₹919.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INDIAGLYCO.BO's P/E ratio is 22.16. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDIAGLYCO.BO's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INDIAGLYCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDIAGLYCO.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, RAIN.NS has a market cap of 51.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while RAIN.NS trades at ₹154.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas RAIN.NS's P/E ratio is -38.74. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RAIN.NS's ROE of -0.02%. Regarding short-term risk, SANGINITA.NS is more volatile compared to RAIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check RAIN.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, RAIN.BO has a market cap of 51.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while RAIN.BO trades at ₹154.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas RAIN.BO's P/E ratio is -38.61. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RAIN.BO's ROE of -0.02%. Regarding short-term risk, SANGINITA.NS is more volatile compared to RAIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check RAIN.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GHCL.BO has a market cap of 44.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GHCL.BO trades at ₹493.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GHCL.BO's P/E ratio is 9.05. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GHCL.BO's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GHCL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GHCL.NS has a market cap of 44.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GHCL.NS trades at ₹493.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GHCL.NS's P/E ratio is 9.05. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GHCL.NS's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GHCL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GHCL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, MFL.NS has a market cap of 44.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while MFL.NS trades at ₹1,062.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas MFL.NS's P/E ratio is 15.94. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to MFL.NS's ROE of +0.39%. Regarding short-term risk, SANGINITA.NS is more volatile compared to MFL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check MFL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, CHEMPLASTS.BO has a market cap of 40B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while CHEMPLASTS.BO trades at ₹254.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas CHEMPLASTS.BO's P/E ratio is -14.01. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to CHEMPLASTS.BO's ROE of -0.15%. Regarding short-term risk, SANGINITA.NS is more volatile compared to CHEMPLASTS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check CHEMPLASTS.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, CHEMPLASTS.NS has a market cap of 40B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while CHEMPLASTS.NS trades at ₹254.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas CHEMPLASTS.NS's P/E ratio is -14.01. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to CHEMPLASTS.NS's ROE of -0.15%. Regarding short-term risk, SANGINITA.NS is more volatile compared to CHEMPLASTS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check CHEMPLASTS.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, EPIGRAL.BO has a market cap of 40B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while EPIGRAL.BO trades at ₹914.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas EPIGRAL.BO's P/E ratio is 11.83. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to EPIGRAL.BO's ROE of +0.18%. Regarding short-term risk, SANGINITA.NS is more volatile compared to EPIGRAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check EPIGRAL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, EPIGRAL.NS has a market cap of 40B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while EPIGRAL.NS trades at ₹916.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas EPIGRAL.NS's P/E ratio is 11.84. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to EPIGRAL.NS's ROE of +0.18%. Regarding short-term risk, SANGINITA.NS is more volatile compared to EPIGRAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check EPIGRAL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, MEGH.NS has a market cap of 35.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while MEGH.NS trades at ₹139.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas MEGH.NS's P/E ratio is 15.63. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to MEGH.NS's ROE of +0.16%. Regarding short-term risk, SANGINITA.NS is more volatile compared to MEGH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check MEGH.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GUJALKALI.BO has a market cap of 35.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GUJALKALI.BO trades at ₹481.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GUJALKALI.BO's P/E ratio is -404.92. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GUJALKALI.BO's ROE of -0.00%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GUJALKALI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GUJALKALI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GUJALKALI.NS has a market cap of 35.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GUJALKALI.NS trades at ₹480.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GUJALKALI.NS's P/E ratio is -404.49. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GUJALKALI.NS's ROE of -0.00%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GUJALKALI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GUJALKALI.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, STYRENIX.NS has a market cap of 33.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while STYRENIX.NS trades at ₹1,922.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas STYRENIX.NS's P/E ratio is 20.39. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to STYRENIX.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to STYRENIX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check STYRENIX.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, STYRENIX.BO has a market cap of 33.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while STYRENIX.BO trades at ₹1,918.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas STYRENIX.BO's P/E ratio is 20.40. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to STYRENIX.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to STYRENIX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check STYRENIX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ELLEN.NS has a market cap of 33.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ELLEN.NS trades at ₹234.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ELLEN.NS's P/E ratio is N/A. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ELLEN.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ELLEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ELLEN.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, RPEL.NS has a market cap of 32.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while RPEL.NS trades at ₹706.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas RPEL.NS's P/E ratio is 65.61. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RPEL.NS's ROE of +0.24%. Regarding short-term risk, SANGINITA.NS is more volatile compared to RPEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check RPEL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, RPEL.BO has a market cap of 32.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while RPEL.BO trades at ₹709.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas RPEL.BO's P/E ratio is 65.41. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RPEL.BO's ROE of +0.26%. Regarding short-term risk, SANGINITA.NS is more volatile compared to RPEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check RPEL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, FOSECOIND.NS has a market cap of 31B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while FOSECOIND.NS trades at ₹4,717.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas FOSECOIND.NS's P/E ratio is 39.14. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to FOSECOIND.NS's ROE of +0.23%. Regarding short-term risk, SANGINITA.NS is less volatile compared to FOSECOIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check FOSECOIND.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, FOSECOIND.BO has a market cap of 30.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while FOSECOIND.BO trades at ₹4,708.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas FOSECOIND.BO's P/E ratio is 38.89. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to FOSECOIND.BO's ROE of +0.23%. Regarding short-term risk, SANGINITA.NS is more volatile compared to FOSECOIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check FOSECOIND.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DDEVPLASTIK.BO has a market cap of 27.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DDEVPLASTIK.BO trades at ₹262.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DDEVPLASTIK.BO's P/E ratio is 14.39. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DDEVPLASTIK.BO's ROE of +0.24%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DDEVPLASTIK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DDEVPLASTIK.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, BEPL.BO has a market cap of 20.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while BEPL.BO trades at ₹81.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas BEPL.BO's P/E ratio is 12.18. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to BEPL.BO's ROE of +0.17%. Regarding short-term risk, SANGINITA.NS is more volatile compared to BEPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check BEPL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, BEPL.NS has a market cap of 20.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while BEPL.NS trades at ₹80.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas BEPL.NS's P/E ratio is 12.04. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to BEPL.NS's ROE of +0.17%. Regarding short-term risk, SANGINITA.NS is more volatile compared to BEPL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check BEPL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, SANSTAR.NS has a market cap of 15.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while SANSTAR.NS trades at ₹86.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas SANSTAR.NS's P/E ratio is 80.37. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SANSTAR.NS's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is more volatile compared to SANSTAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check SANSTAR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DCW.NS has a market cap of 14.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DCW.NS trades at ₹48.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DCW.NS's P/E ratio is 34.17. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DCW.NS's ROE of +0.04%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DCW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DCW.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INEOSSTYRO.NS has a market cap of 14.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INEOSSTYRO.NS trades at ₹807.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INEOSSTYRO.NS's P/E ratio is 11.53. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INEOSSTYRO.NS's ROE of +0.23%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INEOSSTYRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INEOSSTYRO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DCW.BO has a market cap of 14.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DCW.BO trades at ₹48.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DCW.BO's P/E ratio is 28.48. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DCW.BO's ROE of +0.04%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DCW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DCW.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GODAVARIB.NS has a market cap of 14.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GODAVARIB.NS trades at ₹274.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GODAVARIB.NS's P/E ratio is 70.56. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GODAVARIB.NS's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GODAVARIB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GODAVARIB.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, PUNJABCHEM.NS has a market cap of 13.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while PUNJABCHEM.NS trades at ₹1,100.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas PUNJABCHEM.NS's P/E ratio is 22.36. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PUNJABCHEM.NS's ROE of +0.16%. Regarding short-term risk, SANGINITA.NS is more volatile compared to PUNJABCHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check PUNJABCHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, PUNJABCHEM.BO has a market cap of 13.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while PUNJABCHEM.BO trades at ₹1,100.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas PUNJABCHEM.BO's P/E ratio is 22.34. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PUNJABCHEM.BO's ROE of +0.16%. Regarding short-term risk, SANGINITA.NS is more volatile compared to PUNJABCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check PUNJABCHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, IGPL.BO has a market cap of 11.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while IGPL.BO trades at ₹360.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas IGPL.BO's P/E ratio is 34.90. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to IGPL.BO's ROE of -0.01%. Regarding short-term risk, SANGINITA.NS is more volatile compared to IGPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check IGPL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, A1L.BO has a market cap of 10.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while A1L.BO trades at ₹24.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas A1L.BO's P/E ratio is 286.25. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to A1L.BO's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is more volatile compared to A1L.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check A1L.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GEMAROMA.NS has a market cap of 10.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GEMAROMA.NS trades at ₹195.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GEMAROMA.NS's P/E ratio is 36.61. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GEMAROMA.NS's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GEMAROMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GEMAROMA.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ANDHRSUGAR.BO has a market cap of 9.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ANDHRSUGAR.BO trades at ₹72.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ANDHRSUGAR.BO's P/E ratio is 11.81. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ANDHRSUGAR.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ANDHRSUGAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ANDHRSUGAR.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ANDHRSUGAR.NS has a market cap of 9.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ANDHRSUGAR.NS trades at ₹72.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ANDHRSUGAR.NS's P/E ratio is 11.74. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ANDHRSUGAR.NS's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ANDHRSUGAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ANDHRSUGAR.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GULPOLY.NS has a market cap of 9.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GULPOLY.NS trades at ₹156.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GULPOLY.NS's P/E ratio is 12.60. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GULPOLY.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GULPOLY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GULPOLY.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GULPOLY.BO has a market cap of 9.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GULPOLY.BO trades at ₹156.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GULPOLY.BO's P/E ratio is 12.59. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GULPOLY.BO's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GULPOLY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GULPOLY.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ZUARI.BO has a market cap of 9.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ZUARI.BO trades at ₹223.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ZUARI.BO's P/E ratio is 0.98. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ZUARI.BO's ROE of +0.41%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ZUARI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ZUARI.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, AMNPLST.NS has a market cap of 8.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while AMNPLST.NS trades at ₹154.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas AMNPLST.NS's P/E ratio is 25.95. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to AMNPLST.NS's ROE of +0.13%. Regarding short-term risk, SANGINITA.NS is less volatile compared to AMNPLST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check AMNPLST.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, AMNPLST.BO has a market cap of 8.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while AMNPLST.BO trades at ₹155.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas AMNPLST.BO's P/E ratio is 25.82. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to AMNPLST.BO's ROE of +0.13%. Regarding short-term risk, SANGINITA.NS is more volatile compared to AMNPLST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check AMNPLST.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, SRHHYPOLTD.NS has a market cap of 8.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while SRHHYPOLTD.NS trades at ₹476.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas SRHHYPOLTD.NS's P/E ratio is 8.94. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SRHHYPOLTD.NS's ROE of +0.10%. Regarding short-term risk, SANGINITA.NS is more volatile compared to SRHHYPOLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check SRHHYPOLTD.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, SRHHYPOLTD.BO has a market cap of 8.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while SRHHYPOLTD.BO trades at ₹477.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas SRHHYPOLTD.BO's P/E ratio is 8.88. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SRHHYPOLTD.BO's ROE of +0.10%. Regarding short-term risk, SANGINITA.NS is more volatile compared to SRHHYPOLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check SRHHYPOLTD.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ORIENTCQ.BO has a market cap of 8.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ORIENTCQ.BO trades at ₹810.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ORIENTCQ.BO's P/E ratio is 15.88. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ORIENTCQ.BO's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ORIENTCQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ORIENTCQ.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INDOAMIN.NS has a market cap of 7.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INDOAMIN.NS trades at ₹108.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INDOAMIN.NS's P/E ratio is 11.08. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOAMIN.NS's ROE of +0.22%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INDOAMIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOAMIN.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INDOAMIN.BO has a market cap of 7.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INDOAMIN.BO trades at ₹108.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INDOAMIN.BO's P/E ratio is 11.04. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOAMIN.BO's ROE of +0.22%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INDOAMIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOAMIN.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INDOBORAX.NS has a market cap of 7.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INDOBORAX.NS trades at ₹244.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INDOBORAX.NS's P/E ratio is 17.07. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOBORAX.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INDOBORAX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOBORAX.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INDOBORAX.BO has a market cap of 7.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INDOBORAX.BO trades at ₹244.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INDOBORAX.BO's P/E ratio is 16.93. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDOBORAX.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INDOBORAX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDOBORAX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, UNIENTER.NS has a market cap of 7.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while UNIENTER.NS trades at ₹106.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas UNIENTER.NS's P/E ratio is 37.89. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to UNIENTER.NS's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is more volatile compared to UNIENTER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check UNIENTER.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, VALIANTORG.BO has a market cap of 6.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while VALIANTORG.BO trades at ₹234.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas VALIANTORG.BO's P/E ratio is 28.67. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to VALIANTORG.BO's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is more volatile compared to VALIANTORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check VALIANTORG.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, VALIANTORG.NS has a market cap of 6.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while VALIANTORG.NS trades at ₹233.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas VALIANTORG.NS's P/E ratio is 28.38. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to VALIANTORG.NS's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is less volatile compared to VALIANTORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check VALIANTORG.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, SUNSHIEL.BO has a market cap of 6.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while SUNSHIEL.BO trades at ₹826.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas SUNSHIEL.BO's P/E ratio is 26.02. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SUNSHIEL.BO's ROE of +0.25%. Regarding short-term risk, SANGINITA.NS is more volatile compared to SUNSHIEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check SUNSHIEL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, NATPEROX.BO has a market cap of 6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while NATPEROX.BO trades at ₹1,040.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas NATPEROX.BO's P/E ratio is 399.75. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NATPEROX.BO's ROE of -0.02%. Regarding short-term risk, SANGINITA.NS is more volatile compared to NATPEROX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check NATPEROX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DMCC.BO has a market cap of 5.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DMCC.BO trades at ₹221.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DMCC.BO's P/E ratio is 21.09. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DMCC.BO's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DMCC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DMCC.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DMCC.NS has a market cap of 5.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DMCC.NS trades at ₹225.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DMCC.NS's P/E ratio is 21.06. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DMCC.NS's ROE of +0.12%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DMCC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DMCC.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, PRIMO.NS has a market cap of 4.8B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while PRIMO.NS trades at ₹19.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas PRIMO.NS's P/E ratio is 62.28. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PRIMO.NS's ROE of +0.02%. Regarding short-term risk, SANGINITA.NS is more volatile compared to PRIMO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check PRIMO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, OCCLLTD.NS has a market cap of 4.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while OCCLLTD.NS trades at ₹92.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas OCCLLTD.NS's P/E ratio is 12.13. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to OCCLLTD.NS's ROE of +0.09%. Regarding short-term risk, SANGINITA.NS is more volatile compared to OCCLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check OCCLLTD.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ARIES.BO has a market cap of 4.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ARIES.BO trades at ₹329.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ARIES.BO's P/E ratio is 11.49. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ARIES.BO's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ARIES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ARIES.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, SHIVALIK.BO has a market cap of 4.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while SHIVALIK.BO trades at ₹287.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas SHIVALIK.BO's P/E ratio is 30.62. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SHIVALIK.BO's ROE of +0.02%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SHIVALIK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SHIVALIK.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, NAPEROL.BO has a market cap of 3.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while NAPEROL.BO trades at ₹626.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas NAPEROL.BO's P/E ratio is 39.25. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to NAPEROL.BO's ROE of -0.02%. Regarding short-term risk, SANGINITA.NS is more volatile compared to NAPEROL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check NAPEROL.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, KANORICHEM.BO has a market cap of 3.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while KANORICHEM.BO trades at ₹67.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas KANORICHEM.BO's P/E ratio is -4.20. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to KANORICHEM.BO's ROE of -0.08%. Regarding short-term risk, SANGINITA.NS is less volatile compared to KANORICHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check KANORICHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, KANORICHEM.NS has a market cap of 3.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while KANORICHEM.NS trades at ₹68.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas KANORICHEM.NS's P/E ratio is -4.16. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to KANORICHEM.NS's ROE of -0.08%. Regarding short-term risk, SANGINITA.NS is more volatile compared to KANORICHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check KANORICHEM.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DCMSRMIND.BO has a market cap of 3.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DCMSRMIND.BO trades at ₹175.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DCMSRMIND.BO's P/E ratio is 3.63. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DCMSRMIND.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is less volatile compared to DCMSRMIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check DCMSRMIND.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, LORDSCHLO.NS has a market cap of 2.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while LORDSCHLO.NS trades at ₹126.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas LORDSCHLO.NS's P/E ratio is 11.72. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to LORDSCHLO.NS's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to LORDSCHLO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check LORDSCHLO.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, LORDSCHLO.BO has a market cap of 2.9B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while LORDSCHLO.BO trades at ₹129.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas LORDSCHLO.BO's P/E ratio is 11.51. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to LORDSCHLO.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is less volatile compared to LORDSCHLO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check LORDSCHLO.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, OCCL.NS has a market cap of 2.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while OCCL.NS trades at ₹233.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas OCCL.NS's P/E ratio is 77.52. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to OCCL.NS's ROE of +0.02%. Regarding short-term risk, SANGINITA.NS is more volatile compared to OCCL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check OCCL.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DIAMINESQ.BO has a market cap of 2.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DIAMINESQ.BO trades at ₹239.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DIAMINESQ.BO's P/E ratio is -25.50. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DIAMINESQ.BO's ROE of -0.06%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DIAMINESQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DIAMINESQ.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DIAMINESQ.NS has a market cap of 2.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DIAMINESQ.NS trades at ₹233.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DIAMINESQ.NS's P/E ratio is -25.49. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DIAMINESQ.NS's ROE of -0.06%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DIAMINESQ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DIAMINESQ.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, INDGELA.BO has a market cap of 2.3B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while INDGELA.BO trades at ₹323.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas INDGELA.BO's P/E ratio is 8.74. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to INDGELA.BO's ROE of +0.15%. Regarding short-term risk, SANGINITA.NS is more volatile compared to INDGELA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check INDGELA.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, JAYSYNTH.BO has a market cap of 1.7B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while JAYSYNTH.BO trades at ₹12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas JAYSYNTH.BO's P/E ratio is 13.96. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to JAYSYNTH.BO's ROE of N/A. Regarding short-term risk, SANGINITA.NS is more volatile compared to JAYSYNTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check JAYSYNTH.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ISHANCH.NS has a market cap of 1.6B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ISHANCH.NS trades at ₹59.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ISHANCH.NS's P/E ratio is -29.19. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ISHANCH.NS's ROE of -0.08%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ISHANCH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ISHANCH.NS's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, CHEMCRUX.BO has a market cap of 1.5B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while CHEMCRUX.BO trades at ₹98.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas CHEMCRUX.BO's P/E ratio is 70.94. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to CHEMCRUX.BO's ROE of +0.03%. Regarding short-term risk, SANGINITA.NS is more volatile compared to CHEMCRUX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check CHEMCRUX.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, PAUSHAKLTD.BO has a market cap of 1.4B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while PAUSHAKLTD.BO trades at ₹464.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas PAUSHAKLTD.BO's P/E ratio is 31.46. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to PAUSHAKLTD.BO's ROE of +0.08%. Regarding short-term risk, SANGINITA.NS is more volatile compared to PAUSHAKLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check PAUSHAKLTD.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, RESGEN.BO has a market cap of 1.2B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while RESGEN.BO trades at ₹59.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas RESGEN.BO's P/E ratio is 15.24. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to RESGEN.BO's ROE of +0.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to RESGEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check RESGEN.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, DEEPAKCHEM.BO has a market cap of 1.1B. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while DEEPAKCHEM.BO trades at ₹100.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas DEEPAKCHEM.BO's P/E ratio is 9.71. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to DEEPAKCHEM.BO's ROE of +0.19%. Regarding short-term risk, SANGINITA.NS is more volatile compared to DEEPAKCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check DEEPAKCHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, POLYCHEM.BO has a market cap of 888.9M. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while POLYCHEM.BO trades at ₹2,201.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas POLYCHEM.BO's P/E ratio is 4.76. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to POLYCHEM.BO's ROE of +0.40%. Regarding short-term risk, SANGINITA.NS is more volatile compared to POLYCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check POLYCHEM.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ASHOKALC.BO has a market cap of 551.4M. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ASHOKALC.BO trades at ₹119.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ASHOKALC.BO's P/E ratio is -10.04. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ASHOKALC.BO's ROE of +0.05%. Regarding short-term risk, SANGINITA.NS is more volatile compared to ASHOKALC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check ASHOKALC.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, ZR2.BO has a market cap of 548.4M. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while ZR2.BO trades at ₹142.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas ZR2.BO's P/E ratio is 1097.50. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to ZR2.BO's ROE of +0.01%. Regarding short-term risk, SANGINITA.NS is less volatile compared to ZR2.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check ZR2.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, GARODCH.BO has a market cap of 482.7M. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while GARODCH.BO trades at ₹138.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas GARODCH.BO's P/E ratio is 2.03. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to GARODCH.BO's ROE of -1.14%. Regarding short-term risk, SANGINITA.NS is more volatile compared to GARODCH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check GARODCH.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, SHIVAAGRO.BO has a market cap of 379.7M. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while SHIVAAGRO.BO trades at ₹38.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas SHIVAAGRO.BO's P/E ratio is 172.73. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to SHIVAAGRO.BO's ROE of +0.00%. Regarding short-term risk, SANGINITA.NS is less volatile compared to SHIVAAGRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check SHIVAAGRO.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, CAPRO.BO has a market cap of 334M. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while CAPRO.BO trades at ₹72.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas CAPRO.BO's P/E ratio is 7261.00. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to CAPRO.BO's ROE of +0.00%. Regarding short-term risk, SANGINITA.NS is less volatile compared to CAPRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SANGINITA.NS.Check CAPRO.BO's competition here

SANGINITA.NS plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SANGINITA.NS stands at 389M. In comparison, HARLETH.BO has a market cap of 289.6M. Regarding current trading prices, SANGINITA.NS is priced at ₹14.70, while HARLETH.BO trades at ₹59.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SANGINITA.NS currently has a P/E ratio of -11.47, whereas HARLETH.BO's P/E ratio is 11.94. In terms of profitability, SANGINITA.NS's ROE is -0.06%, compared to HARLETH.BO's ROE of +0.04%. Regarding short-term risk, SANGINITA.NS is more volatile compared to HARLETH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SANGINITA.NS.Check HARLETH.BO's competition here